SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare informs about press release

01 Apr 2016 Evaluate

Cadila Healthcare has informed about a Press Release dated April 01, 2016 titled ‘Zydus receives final approval from the USFDA for Carboplatin Injection’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1070.60 -3.70 (-0.34%)
19-Jun-2026 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1838.35
Dr. Reddys Lab 1272.35
Cipla 1356.15
Zydus Lifesciences 1070.60
Lupin 2347.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: